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Abstract 
Improved outcome in the treatment of child-
hood cancer results not only from more aggres-
sive  and  tailored  cancer-directed  therapy,  but
also from improved supportive therapy and treat-
ment  of  life-threatening  infectious  complica-
tions. Prompt and aggressive intervention with
empiric antibiotics has reduced mortality in this
group of patients. Physical examination, blood
tests, and blood cultures must be performed, and
antibiotic therapy must be administered as soon
as possible. Beta-lactam monotherapy, such as
piperacillin-tazobactam or cefepime, may be an
appropriate empiric therapy of choice for all clin-
ically stable patients with neutropenic fever. An
anti-pseudomonal  beta-lactam  antibiotic  plus
gentamicin is recommended for patients with
systemic compromise. 
Introduction
The recent advances and improved outcome
in the treatment of childhood cancer observed
over the last decades result not only from more
aggressive and better tailored cancer-directed
therapy,  but  also  from  improved  supportive
therapy.1 In solid tumors, more aggressive sur-
gery, supported by more effective anesthesia
techniques  and  refined  radiotherapy,  has
made a significant contribution to improved
outcome.  In  leukemia,  improved  outcome  is
mainly  due  to  more  effective  chemotherapy.
This is achieved with repeated use of multi-
agent  courses,  also  resulting  in  repeated
episodes of deep and extended cytopenia, and
in  particular  neutropenia.  Eighty  percent  of
post-chemotherapy  neutropenic  episodes
which last more than one week are complicat-
ed by fever, and about 60% of them have an
infectious  etiology.2 In  selected  situations,
such  as  children  with  high  burden  of  acute
lymphoblastic leukemia, the risk of failure to
achieve first complete remission by the end of
the first month of induction therapy can be
comparable or even higher, at least in some
chemotherapy programs, to that of life-threat-
ening infectious complications.3-6 Thus, since
prompt  and  aggressive  intervention  with
empiric  antibiotics  has  reduced  mortality  in
this group of patients,2-4 the role of anti-infec-
tive therapy is now considered an important
element  of  the  application  of  current
chemotherapy regimens.
Although much attention has been paid to
the role of invasive fungal infections in the
immune compromised host, it is important to
remember  that  85%  of  febrile  episodes  still
have bacterial origin and, therefore, identifica-
tion and treatment of septicemia in the child
with cancer remains a very important issue for
the specialist physician.6
Throughout the 1960s and 1970s, gram-neg-
ative organisms were most frequently isolated
from  patients  with  nosocomial  blood  stream
infections. Since then, infections due to gram-
positive organisms have become increasingly
frequent, from 62% in 1995 to 76% in 2000.7 In
addition, over the past two decades, antibiotic
resistance  rates  rose  for  all  predominant
organisms,  including  Staphylococcus  aureus,
coagulase-negative staphylococci, enterococci,
and  gram-negative  pathogens.  Thus,  antimi-
crobial  prophylaxis  and  treatment  have
become increasingly difficult, and timely and
accurate epidemiological information is need-
ed to guide appropriate empirical therapy.8
Definitions
Fever
Increased  central  body  temperature  above
normal values. Word Health Organization fever
definition was used: body temperature above
38°C (standard readings 36.5-37°C). Fever of
unknown  origin  (FUO)  is  defined  as  fever
without a known cause. According to Italian
Society of Pediatrics guidelines, body tempera-
ture  was  measured  in  tympanic  membrane
with an infrared radiation thermometer.
Neutropenia
Total neutrophil count of less than 1ﾥ109/L
in children below one year of age and less than
1.5ﾥ109/L  in  patients  older  than  one  year.
Slight  neutropenia  is  defined  as  1-1.5ﾥ109/L
neutrophils,  moderate  between  0.5-1ﾥ109/L,
deep for neutrophils less than 0.5ﾥ109/L.
Sepsis
Sepsis-related terminology.
Systemic inflammatory response
syndrome
Body  temperature  more  than  38.5°C,  less
than 36°C, tachycardia above SD for age, respi-
ratory rate above SD for age, white cell count
above  or  below  age-related  normal  values
(Table 1).
Sepsis
SIRS  in  presence  of  proven  or  suspected
infection.
Severe sepsis
Sepsis with cardiovascular dysfunction, res-
piratory distress syndrome, or organ dysfunc-
tion  (>2)  (including  neurological,  renal,
hepatic, hematologic).
Septic shock
Sepsis  with  cardiovascular  dysfunction,
including  hypotension,  vasopressor  depend-
ence  acidosis,  elevated  lactate  oliguria,
delayed capillary refill rate, core to peripheral
temperature gap of more than 3°C.10
Monomicrobial sepsis
One pathogenous (bacteria or fungus) iso-
lated from hemocolture. In cases of staphylo-
cocci  coagulase-negative,  corynebacteria
(except for C. jeikeium) or other cutaneus skin
contaminant: two different positive hemocol-
tures in 24 h are needed or the same pathogen
must be isolated from hemocolture and anoth-
er site of infection (cellulitis/abscess).
Polimicrobial sepsis
Two or more different pathogens from the
same  hemocolture,  or  from  different  ones
taken within 24 h.
Central venous catheter related
sepsis
Fever (>38°C) with shivering within 2 h of
CVC handling associated with positive hemo-
colture and/or: relevant pathogen isolated from
CVC  but  not  from  peripheral  blood  sample;
same  pathogen  isolated  from  CVC  tip/sleeve
(after  CVC  removal)  and  from  blood  sample
collected  through  catheter;  positivity  for  a
pathogen  from  CVC  tip/sleeve  (after  CVC
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removal), but not from peripheral blood sam-
ple; pathogen isolated from blood culture and
from CVC emergency secretion or from CVC
subcutaneous tunnel.
Initial patient evaluation and
risk assessment
All  children  with  cancer  undergoing
chemotherapy, and thus at risk for severe neu-
tropenia,  should  be  assessed  immediately
when fever appears.2,4,6 A seemingly well child
can progress to irrevocable septic shock in a
very short period of time. It is important to
remember  that  concurrent  steroid  therapy,
especially with high-dose dexamethasone, can
increase the risk that fever is falsely low or
absent at the onset of septicemia. Thus, during
these  kinds  of  therapies,  parents  should  be
appropriately trained to recognize that, when
the child’s clinical picture appears to change
with  (but  even  without)  fever,  they  must
inform the medical team if the child is being
treated as an outpatient. Fever in neutropenic
patients  represents  an  emergency,  and  it  is
mandatory to start an empiric antibiotic thera-
py immediately.11 Since this practice found a
common consensus, the mortality rate in chil-
dren has decreased from 1% to 0.4%.12
Children with febrile neutropenia should be
evaluated as soon as they get to the hospital.
Initial  physical  inspection,  including  vital
signs, should be performed as soon as possible.
In  the  case  of  clinical  signs  of  septicemia,
aggressive  fluid  resuscitation  and  inotropic
support is mandatory. In an apparently stable
child,  detailed  history  should  include  recent
chemotherapy or other treatment to assess the
likelihood of severe neutropenia even before
performing a blood count. Specific questions
should address the possible exposure to oppor-
tunistic infections (e.g. tuberculosis) and the
previous history of clinically relevant infection
or  colonization.  The  duration  of  fever,  pres-
ence of rigors and dizziness, and fluid intake
and output are important. Any indication of a
Review
Table 2. Patient evaluation (modified from NCCN guidelines).13
Initial clinical Findings Evaluation Addition to initial empiric regimen
presentation
Mouth/mucosal membrane • Necrotizing ulceration • Culture and gram stains o Adequate anaerobic activity?
(HSV, fungal, leukemic infiltrate) o Anti-HSV therapy?
o Systemic antifungal therapy?
• Biopsy suspicious lesions
• Thrush o Antifungal therapy (fluconazole)
• Vescicular lesions • Viral cultures/PCR +  o Anti HSV therapy 
direct fluorescent ab tests
for HSV/VZV
Esophagus 1. Retrosternal burning • Cultures suspicious oral lesions o Initial therapy guided by clinical findings
2. Dysphagia/odynophagia (HSV, fungal) o Antifungal therapy for thrush
• Endoscopy if no response to therapy o Acyclovir for possible HSV
• CMV esophagitis in pt at high risk
Abdominal pain • Abdominal CT/ultrasound o Metronidazole if C. difficile
• Alkaline phosphatase, transaminases, o Adequate anaerobic therapy?
bilirubine, amilase, lipase
Perirectal pain  • Perirectal inspection  o Ensure adequate anaerobic therapy
• Consider abdominal/pelvic CT o Consider enterococcal coverage 
o Consider local care 
Vascular access devices (VAD) 1. Entry or exit inflammation • Swab exit site drainage for culture o Vancomycin initially or add it if site not
• Blood culture from each VAD port responding after 48 h empiric therapy
2. Tunnel infection/port pocket • Blood culture from each VAD port o Remove catheter and culture surgical
infection, septic phlebitis wound
o Add vancomycin
Lung infiltrates 1. Low risk • Blood and sputum cultures o Azitromyci/fluoroquinolone
• Nasal wash for respiratory viruses, o Antiviral?
rapid tests o Vancomycin/linezolid?
• Legionella urine Ag test
• Consider BAL, particulary if no response
to initial therapy or if diffuse infiltrates
present
• Blood and sputum cultures
2. Intermediate to high risk • See low risk o Azithromycin/fluoroquinolone
• CT chest to better define infiltrates o Mold active antifungal agent?
o Antiviral?
o TMP_SMX?
o Vancomycin/linezolid?
Table 1. Systemic inflammatory response syndrome.9
Age (yr) Respiratory rate (breaths/min) Heart rate (beats/min)
<1 30-60 100-160
1-2 24-40 90-150
2-5 22-34 80-140
6-12 18-30 70-120
>12 12-16 60-100[Pediatric Reports 2012; 4:e2] [page 7]
focus of infection should be sought. This could
include  one  of  the  following:  mucositis,
headache, cough, local swelling, cellulitis, irri-
tation or itching at the site of the indwelling
intravenous catheter, dysuria, frequency and
pain on passing stools.2,4,6 The gastrointestinal
system  must  also  be  carefully  examined  as
typhlitis or neutropenic enterocolitis is a com-
mon  cause  of  severe  infections  (Table  2).
Although a positive history may indicate the
causative organism, very often there will be no
clear source of infection, as the child with neu-
tropenia  is  unable  to  produce  an  adequate
inflammatory response, and therefore has no
localizing signs. 
On the basis of the initial evaluation, the
physician may be asked to decide on several
issues which are clinically relevant: selection
of initial choice of empiric antibiotic therapy,
including  type  and  route  of  administration,
and  the  need  for  patient  admission.14 To
address this issue, attempts have been made to
build and validate methods to define the indi-
vidual patient risk for early complication. An
example of the scoring system adopted by the
American  Society  of  Hematology  (ASH)  in
2001 is summarized in Table 3. Only patients
at risk for septicemia fall within the scope of
this review. 
Diagnostic studies
According to the guidelines developed by the
Associazione  Italiana  Ematologia  Oncologia
Pediatrica (AIEOP)  for  the  management  of
febrile neutropenia, at least two separate blood
culture sets have to be collected and inoculat-
ed into an aerobic bottle; if abdominal signs
are  present  an  anaerobic  bottle  must  be
added.15 Initial,  and  then  daily,  tests  should
include full blood examination (FBE) with dif-
ferential  white  cell  count,  urea,  electrolytes
and serum creatinine, liver function, CRP, pro-
calcitonin. Cultures from other sites should be
taken according to clinical indication. A chest
X-ray is indicated for patients with respiratory
symptoms or signs.4,6,14,15 Other specific diag-
nostic tools are suggested in Table 2. 
Antibiotic therapy
Despite the relevance of the topic, consen-
sus is still lacking on initial treatment of chil-
dren with suspected septicemia during febrile
neutropenia.16 Although data on patient’s his-
tory, allergies, symptoms, signs, recent antibi-
otic use and culture data, as well as local flora
and infection patterns, are relevant, they may
be insufficiently informative to direct individ-
ual  treatment.  Meta-analyses  of  randomized
controlled  trials  in  sepsis  have  shown  that
monotherapy with an antipseudomonal beta-
lactam (e.g. piperacillin-tazobactam, cefepime,
ceftazadime, meropenem) is as efficacious as
combination therapy.15-17 Piperacillin-tazobac-
tam or cefepime appear to be a very reasonable
choice for first-line monotherapy.17-18 Analysis
of local epidemiology must support this choice,
by ruling out clusters of multi-resistant strains
of Gram-negative bacteria (Table 4). Patients
with impaired renal function (glomerular fil-
tration rate less than 50 mL/min) will require
adjustments to the suggested doses based on
calculated creatinine clearance.17-18
There is also no evidence that combination
regimens prevent the emergence of resistant
organisms. The potential risk of nephrotoxici-
ty  with  betalactam/aminoglycoside  combina-
tion therapy may outweigh any potential bene-
fit.17-18
Overall, individual institutions treating chil-
dren with cancer should design and implement
a  careful,  ongoing  data-collection  allowing
monitoring of the local epidemiology of bacter-
ial infection. This will form the basis for a def-
inition of the institutional protocol for empiric
antibiotic  therapy  for  febrile  neutropenia,
especially in high-risk patients.16
Use of glycopeptides
With the increasing rate of gram positive
infections in neutropenic patients (in particu-
lar  those  caused  by  methicillin-resistant
staphylococci and enterococci) the use of gly-
copeptides  as  part  of  initial  empirical  treat-
ment has become controversal.15,17,18
At  present,  despite  the  high  incidence  of
these kind of infections, the only indications
for the use of this class of antibiotics are in
cases of severe sepsis or septic shock, strong
suspicion of cutaneous, soft tissues, CVC relat-
ed infection or in the centers with a very high
rate of gram-positive infections. 15,17,18
In  patients  with  vancomicin-resistant
staphylococci infection, linezolid proved to be
effective and safe in pediatric patients.20
Review
Table 3. Risk Assessment: ASH 2001 Guidelines.11
High risk - Deep and prolonged neutropenia (ANCA<100cell/mm3)
- Hematologic malignancy
- Allogeneic MBT 
- Significant comorbidities
- Shock signs or symptoms/complicated infection
Medium risk  - Solid tumor / high-dose CT / autologous BMT
- Neutropenia between 7-14 days
- Irrelevant comorbidities
- Clinical and hemodynamic stability
Low risk - Solid tumor / standard CT
- Neutropenia <7 days
- No comorbidities
- Clinical and hemodynamic stability
- FUO/non-complicated infection
Table 4. Organisms implicated in febrile neutropenia.
Gram positive Gram negative Fungi Viruses
Staphylococcusspp. (S. epidermidis S. aureus) Enterobacteriaceae(E. coli, Candidaspp. Herpes simplex virus
Coagulase-negative staphylococci Klebsiella spp., Enterobacter spp., Aspergillusspp. Varicella zoster virus
Streptococcusspp. (alpha-haemolytic)and Serratia spp.) Zygomycetes Cytomegalovirus
pyogenes, pneumoniae Pseudomonas aeruginosa Fusarium spp. Epstein-Barr virus
Viridans group Stenotrophomonas maltophilia Adenovirus
Enterococcusspp. (E. faecium) including Influenza virus
vancomycin-resistant strains Anaerobes Para-influenza virus
Bacillus spp. (B. cereus)
Clostridiumspp. (C. difficile) Respiratory syncytial virus
Literia monocytogrnus
Modified from Pizzo and Poplack.19[page 8] [Pediatric Reports 2012; 4:e2]
Modification of empiric therapy
The  median  time  of  defervescence  in
patients  successfully  treated  with  frontline
antibiotic is 3-5 days. Therefore, escalation of
antibiotic  coverage  should  not  occur  prior  to
this period in the absence of clinical instability,
isolation of resistant microorganism or emer-
gence of new infection loci (Table 5).15,17,18
Duration of therapy
Length of therapy is basically guided by neu-
trophil  pattern  and  by  the  bacterial  isolate,
when proven.12,14-18,20 If defervescence occurs
in 3-5 days of treatment, neutrophils count is
more than 500/mm3 and the patient remains
apiretic for more than 48 h, antibiotic therapy
can  be  stopped.14,21 If  the  neutrophil  count
remains  low,  the  approach  is  controversial,
although  it  is  generally  accepted  that:  if
patient’s clinical conditions are good and sta-
ble, the treatment can be interrupted after 5-7
days of apyrexia; in case of profound neutrope-
nia and unstable condition, treatment should
not  be  stopped;  if  neutrophil  count  is  more
than 500/mm3, but the patient is still febrile
despite  a  wide-spectrum  antibiotic  therapy,
fungal, mycobacterial or viral infection should
be suspected15,17,18 (Table 6).
Conclusions
Physical examination, blood tests (in partic-
ular: full blood count, electrolytes, creatinine,
CRP, procalcitonin), and blood cultures should
be performed, and wide range antibiotic thera-
py be administered as soon as possible. Beta-
lactam  monotherapy,  such  as  piperacillin-
tazobactam or cefepime, is the empiric therapy
of choice for all clinically stable patients with
neutropenic fever. Combination therapy with
an  antipseudomonal  beta-lactam  antibiotic
plus aminoglicoside  is  recommended  for
Review
Table 6. Dose range of principals antibiotics used in pediatric neutropenic patients.
Drug  Dose  Comments
Vancomicina 10 mg/kg q6h Vancomycin is active against virtually all strains of community-acquired
methicillin-resistant Staphylococcus aureus(CA-MRSA) and should be used
for all life-threatening and severe infections.
Linezolid </=12yo: 10 mg/kg/dose q8h
> 12 yo: 10 mg/kg/dose q12h
Daptomycina 4 mg/kg / ev /die See also Abdel-Rahman SM, et al.22
Dalfopristin/quinopristin VRE 7.5 mg/kg/dose q8h Only in central venous line
Skin infection 7.5 mg/kg/dose q12h
Imipemen 10-15 mg/kg .6h ( max 4 gr/die)
Meropemen 20-30 mg/kg/dose q8h
Piperacillin/Tazobactam 75-100 mg/kg/dose q6h
Cefepime  50 mg/kg/dose q8h
Cefotaxime 50 mg/kg/dose q6-8h
Ceftazidime 50 mg/kg/dose q8h
Ceftriaxone  80-100 mg/kg/d once daily
Ciprofloxacine IV: 15 mg/kg/dose q8h
Levofloxacine </= 5 yo10 mg/kg/dose q12h 
> 5 yo10 mg/kg/dose q24h
Gentamicin 2.5 mg/kg/dose q8h
Amikacin 18-20 mg/kg/die  Charnas R, Luthi AR, Ruch W.23
EORTC.24
Tobramycin 2.5 mg/kg/dose q8h
TMP/SMX 20 mg TMP/100 mg SMX/kg div. 6 hrly For therapy
Metronidazole 7.5-10 mg/kg/dose
q6-8h
Modified from NCCN guidelines 2011-11-02 ,UMHS Guidelines for Antimicrobial Use, Philip A. Pizzo, MD David G. Poplack Principles and Practice of Pediatric Oncology, 6th edition 2011.
Table 5. Modification of empiric antibiotic therapy during the course of neutropenic fever.
Time/condition Reason for acting and action
Modify initial antibiotic regimen   • clinical instability
within 3-5 days only for reasons specified • isolation of a resistant organism
• persistent positive blood cultures
• emergence of new infective foci
• severe intolerance to antibiotic therapy
• clinical suspicion for uncovered microorganisms:
1. CVC related infection ₒGram positive cocchi
2. Perianal cellulitis/tiflitis ₒenterococci, anaerobi, Gram negative enterobacteria
3. Pneumonia ₒ fungi, mycoplasma, legionella, PCP
After 5-7 days of persistent fever despite a broad spectrum Addition of antifungal therapy? Only in high-risk patients on a preemptive
antibacterial regimen and no identified fever source  approach with evaluation of possible infection (TC - Galactomannan antigen)[Pediatric Reports 2012; 4:e2] [page 9]
patients  with  systemic  compromise.
Vancomycin  is  not  recommended  as  initial
empiric therapy unless there is systemic com-
promise or an approved indication for its use.
Patients who have been assessed as low-risk
for medical complications may be switched to
oral antibiotics and considered for early dis-
charge.  The  choice  of  institutional  initial
empiric antibiotic therapy should always also
consider the local epidemiology based on infor-
mation available from periodic surveys. 
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